[HTML] cell.comFull View

[HTML][HTML] Kinetics of RTK activation determine ERK reactivation and resistance to dual BRAF/MEK inhibition in melanoma

S Kim, R Carvajal, M Kim, HW Yang - Cell Reports, 2023 - cell.com
The combination of BRAF and MEK inhibitors (BRAFi/MEKi) has shown promising response
rates in treating BRAF-mutant melanoma by inhibiting ERK activation. However, treatment …
被引用次数：9 相关文章

Kinetics of RTK activation determine ERK reactivation and resistance to dual BRAF/MEK inhibition in melanoma

S Kim, R Carvajal, M Kim, HW Yang - Cell reports, 2023 - pubmed.ncbi.nlm.nih.gov
The combination of BRAF and MEK inhibitors (BRAFi/MEKi) has shown promising response
rates in treating BRAF-mutant melanoma by inhibiting ERK activation. However, treatment …
[HTML] cell.com

[HTML][HTML] Kinetics of RTK activation determine ERK reactivation and resistance to dual BRAF/MEK inhibition in melanoma

S Kim, R Carvajal, M Kim, HW Yang - Cell Reports, 2023 - cell.com
The combination of BRAF and MEK inhibitors (BRAFi/MEKi) has shown promising response
rates in treating BRAF-mutant melanoma by inhibiting ERK activation. However, treatment …
[HTML] sciencedirect.com

[HTML][HTML] Kinetics of RTK activation determine ERK reactivation and resistance to dual BRAF/MEK inhibition in melanoma

S Kim, R Carvajal, M Kim, HW Yang - Cell Reports, 2023 - Elsevier
The combination of BRAF and MEK inhibitors (BRAFi/MEKi) has shown promising response
rates in treating BRAF-mutant melanoma by inhibiting ERK activation. However, treatment …

Kinetics of RTK activation determine ERK reactivation and resistance to dual BRAF/MEK inhibition in melanoma.

S Kim, R Carvajal, M Kim, HW Yang - Cell Reports, 2023 - europepmc.org
The combination of BRAF and MEK inhibitors (BRAFi/MEKi) has shown promising response
rates in treating BRAF-mutant melanoma by inhibiting ERK activation. However, treatment …